Skip to main content

Drug Interactions between allopurinol and oxtriphylline

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

allopurinol oxtriphylline

Applies to: allopurinol and oxtriphylline

Consumer information for this interaction is not currently available.

MONITOR: Allopurinol may inhibit the metabolism of xanthines (e.g., theophylline), possibly increasing serum concentrations and the risk of toxicity. When theophylline was coadministered with allopurinol, a 25% increase in steady-state theophylline serum concentrations were observed. This interaction may be more likely to occur with daily allopurinol doses of 600 mg or more. The mechanism may related to allopurinol's inhibition of xanthine oxidase, an enzyme involved in the metabolism of theophylline.

MANAGEMENT: Closer clinical and laboratory monitoring for adverse effects is advised if theophylline is used concomitantly with allopurinol. Additionally, theophylline levels should be more closely monitored following the initiation or discontinuation of allopurinol treatment, and the theophylline dosage adjusted as necessary in accordance with the prescribing information. Patients should be advised to report any signs of theophylline toxicity to their doctor (e.g., nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat).

References

  1. Upton RA (1991) "Pharmacokinetic interactions between theophylline and other medication (Part II)." Clin Pharmacokinet, 20, p. 135-50
  2. Manfredi RL, Vesell ES (1981) "Inhibition of theophylline metabolism by long-term allopurinol administration." Clin Pharmacol Ther, 29, p. 224
  3. Barry M, Feely J (1990) "Allopurinol influences aminophenazone elimination." Clin Pharmacokinet, 19, p. 167
  4. (2024) "Product Information. Allopurinol (Sandoz) (allopurinol)." Sandoz Pty Ltd
  5. (2021) "Product Information. Zyloric (allopurinol)." Aspen Pharma Trading Ltd
  6. (2021) "Product Information. Zyloprim (allopurinol)." AA Pharma Inc, 248178
  7. (2024) "Product Information. Allopurinol (allopurinol)." Actavis U.S. (Purepac Pharmaceutical Company)
View all 7 references

Drug and food interactions

Moderate

allopurinol food

Applies to: allopurinol

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: The tolerability of allopurinol may be improved by giving it after a meal. Additionally, when the dose is greater than 300 mg, dividing the total daily dose into smaller doses administered more often may be appropriate to help minimize gastrointestinal irritation.

MONITOR: Concomitant use of allopurinol with central nervous system (CNS) depressants, including alcohol, may potentiate adverse effects such as somnolence and sedation.

MANAGEMENT: To improve tolerability, some manufacturers suggest administering allopurinol after a meal. Additionally, if the daily dose is greater than 300 mg, administering allopurinol in divided doses may help reduce gastrointestinal intolerance. Patients should also be counseled to avoid or limit consumption of alcohol and to avoid activities requiring mental alertness such as driving or operating hazardous machinery until they know how the medication affects them.

References

  1. (2024) "Product Information. Allopurinol (Sandoz) (allopurinol)." Sandoz Pty Ltd
  2. (2021) "Product Information. Zyloric (allopurinol)." Aspen Pharma Trading Ltd
  3. (2021) "Product Information. Zyloprim (allopurinol)." AA Pharma Inc, 248178
  4. (2024) "Product Information. Allopurinol (allopurinol)." Actavis U.S. (Purepac Pharmaceutical Company)
View all 4 references

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.